Zimmer Biomet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zimmer Biomet and other ETFs, options, and stocks.

About ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. 

CEO
Ivan Tornos
CEOIvan Tornos
Employees
17,000
Employees17,000
Headquarters
Warsaw, Indiana
HeadquartersWarsaw, Indiana
Founded
1927
Founded1927
Employees
17,000
Employees17,000

ZBH Key Statistics

Market cap
17.51B
Market cap17.51B
Price-Earnings ratio
23.64
Price-Earnings ratio23.64
Dividend yield
1.05%
Dividend yield1.05%
Average volume
2.50M
Average volume2.50M
High today
$92.60
High today$92.60
Low today
$88.61
Low today$88.61
Open price
$89.65
Open price$89.65
Volume
1.46M
Volume1.46M
52 Week high
$108.29
52 Week high$108.29
52 Week low
$79.12
52 Week low$79.12

Stock Snapshot

With a market cap of 17.51B, Zimmer Biomet(ZBH) trades at $90.49. The stock has a price-to-earnings ratio of 23.64 and currently yields dividends of 1.05%.

On 2026-07-15, Zimmer Biomet(ZBH) stock traded between a low of $88.61 and a high of $92.60. Shares are currently priced at $90.49, which is +2.1% above the low and -2.3% below the high.

Zimmer Biomet(ZBH) shares are trading with a volume of 1.46M, against a daily average of 2.5M.

During the past year, Zimmer Biomet(ZBH) stock moved between $79.12 at its lowest and $108.29 at its peak.

During the past year, Zimmer Biomet(ZBH) stock moved between $79.12 at its lowest and $108.29 at its peak.

ZBH News

Simply Wall St 15h
Did Zimmer Biomet's New Asia Pacific Chief Just Reframe Its Robotics Investment Narrative?

Zimmer Biomet Holdings has appointed Chintan Desai as president of its Asia Pacific Region, effective 14 July 2026, succeeding long-time regional leader Sang Yi...

Did Zimmer Biomet's New Asia Pacific Chief Just Reframe Its Robotics Investment Narrative?
Simply Wall St 4d
Is Zimmer Biomet Holdings Undervalued Following New Credit Facilities And Growth Plans?

Zimmer Biomet Holdings (ZBH) stock is back in focus after the company entered new unsecured revolving credit facilities totaling up to $2.75b, a move that refre...

Is Zimmer Biomet Holdings Undervalued Following New Credit Facilities And Growth Plans?
TipRanks 5d
Zimmer Biomet’s Mymobility Knee ROM Study Signals Growing Digital Edge in Joint Care

Zimmer Biomet Holdings (ZBH) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index o...

Analyst ratings

69%

of 29 ratings
Buy
27.6%
Hold
69%
Sell
3.4%

More ZBH News

TipRanks 7d
Zimmer Biomet Kept at Hold as Analyst Awaits Proof of Salesforce Overhaul, Margin Stability and Robotics‑Driven Upside

, an analyst from BMO Capital, has initiated a new Hold rating on Zimmer Biomet Holdings (ZBH). 4th of July Sale - 70% Off Unlock powerful investing tools and d...

TipRanks 7d
Zimmer Biomet initiated with a Market Perform at BMO Capital

BMO Capital initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95 price target Published first on TheFly – the ultimate source for rea...

People also own

Based on the portfolios of people who own ZBH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.